As inefficient code increases enterprises’ expenditure, vendors are looking at different ways to optimize code — from ...

The standard measure of lesion count may matter less than the underlying biology driving treatment response in ...

F rom the outside, autism can be difficult to understand. The unique sensory world of an autistic person can mean that a ...

The X-Men have always stood out in the superhero genre because of their focus on diversity, individuality, and the struggles ...

A Kennedy adviser said he wants to preserve the Vaccine Injury Compensation Program. The health secretary's anti-vaccine ...

After releasing two gene-edited rice varieties in May this year, scientists are now focusing on developing GE varieties of ...

Researchers sought to determine whether adding fixed-duration venetoclax to RBAC in the first line would be effective in older patients with high-risk MCL.

Despite the importance of GoF modifications, they have sometimes faced misplaced concerns or opposition that could lead to their being overregulated or even banned.

Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference December 8, 2025 8:00 ...

Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease December 1, 2025 8:00 ...